VYNE Therapeutics (NASDAQ:VYNE – Get Rating)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued on Friday, TipRanks reports. They currently have a $7.00 price objective on the stock. Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of VYNE Therapeutics in a report on Friday, March 18th. […]
Related Keywords
, Goldman Sachs Group Inc , Therapeutics Company Profile Get Rating , Beacon Pointe Advisors , Renaissance Technologies , Cantor Fitzgerald , Mackenzie Financial Corp , Therapeutics Inc , Bailard Inc , Get Rating , Pointe Advisors , Financial Corp , Goldman Sachs Group , Sachs Group , Company Profile , Vyne Therapeutics , Nasdaq Vyne , Vyne , Medical , Reiterated Rating , Hc Wainwright ,
comparemela.com © 2020. All Rights Reserved.